Nicox Executive Interview Edison Group In this interview, recently appointed chief scientific officer doug hubatsch describes his prior experience in bringing glaucoma and dry eye pharmaceuticals to market and what prompted him to join nicox and help advance its product development pipeline. Nicox develops drugs for eye diseases, with lead candidate ncx 470 in phase iii trials targeting the topical ocular treatment of glaucoma.
Nicox Executive Interview Edison Group In this interview, we speak to christian koch, deputy head of investment management at bb biotech (bion). Edison advisors leverages our core research platform to provide differentiated services including investor relations, esg and strategic consulting. all interviews have been prepared and issued by edison for publication globally. Vivienne parry talks to michele garufi, ceonicox is an international ophthalmology company developing innovative solutions to help maintain vision and improv. Nicox develops drugs for eye diseases, with lead candidate ncx 470 in phase iii trials targeting the topical ocular treatment of.
Irlab Therapeutics Executive Interview Edison Group Vivienne parry talks to michele garufi, ceonicox is an international ophthalmology company developing innovative solutions to help maintain vision and improv. Nicox develops drugs for eye diseases, with lead candidate ncx 470 in phase iii trials targeting the topical ocular treatment of. In this interview, andreas segerros, chief executive officer of nicox, describes his prior experiences of bringing a leading glaucoma drug to market and what attracted him to join nicox and help advance its product development pipeline. France based nicox develops therapeutics for the treatment of ocular conditions. lead candidate ncx 470 is in phase iii studies for the treatment of glaucoma and it is advancing ncx 4251 for dry eye disease. Nicox develops therapeutics for eye diseases, with lead candidate ncx 470 in phase iii development for the topical ocular treatment of glaucoma. Nicox is a french pharmaceutical company seeking to become an ophthalmology specialist. its core nitric oxide donating platform creates new versions of existing drugs.
Seraphim Executive Interview Edison Group In this interview, andreas segerros, chief executive officer of nicox, describes his prior experiences of bringing a leading glaucoma drug to market and what attracted him to join nicox and help advance its product development pipeline. France based nicox develops therapeutics for the treatment of ocular conditions. lead candidate ncx 470 is in phase iii studies for the treatment of glaucoma and it is advancing ncx 4251 for dry eye disease. Nicox develops therapeutics for eye diseases, with lead candidate ncx 470 in phase iii development for the topical ocular treatment of glaucoma. Nicox is a french pharmaceutical company seeking to become an ophthalmology specialist. its core nitric oxide donating platform creates new versions of existing drugs.
Comments are closed.